138 related articles for article (PubMed ID: 22476388)
1. Linkage disequilibrium between the CYP2C19*17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population.
Pedersen RS; Christensen MM; Brøsen K
Eur J Clin Pharmacol; 2012 Oct; 68(10):1463-4. PubMed ID: 22476388
[No Abstract] [Full Text] [Related]
2. Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations.
Pedersen RS; Brasch-Andersen C; Sim SC; Bergmann TK; Halling J; Petersen MS; Weihe P; Edvardsen H; Kristensen VN; Brøsen K; Ingelman-Sundberg M
Eur J Clin Pharmacol; 2010 Dec; 66(12):1199-205. PubMed ID: 20665013
[TBL] [Abstract][Full Text] [Related]
3. Similarity in recombination rate and linkage disequilibrium at CYP2C and CYP2D cytochrome P450 gene regions among Europeans indicates signs of selection and no advantage of using tagSNPs in population isolates.
Pimenoff VN; Laval G; Comas D; Palo JU; Gut I; Cann H; Excoffier L; Sajantila A
Pharmacogenet Genomics; 2012 Dec; 22(12):846-57. PubMed ID: 23089684
[TBL] [Abstract][Full Text] [Related]
4. Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians.
Suarez-Kurtz G; Genro JP; de Moraes MO; Ojopi EB; Pena SD; Perini JA; Ribeiro-dos-Santos A; Romano-Silva MA; Santana I; Struchiner CJ
Pharmacogenomics J; 2012 Jun; 12(3):267-76. PubMed ID: 21173785
[TBL] [Abstract][Full Text] [Related]
5. Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.
Martis S; Peter I; Hulot JS; Kornreich R; Desnick RJ; Scott SA
Pharmacogenomics J; 2013 Aug; 13(4):369-77. PubMed ID: 22491019
[TBL] [Abstract][Full Text] [Related]
6. Genetic variation in the CYP2C monooxygenase enzyme subfamily shows no association with longevity in a German population.
Flachsbart F; Ufer M; Kleindorp R; Nikolaus S; Schreiber S; Nebel A
J Gerontol A Biol Sci Med Sci; 2011 Nov; 66(11):1186-91. PubMed ID: 21798861
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese.
Zhou Q; Yu XM; Lin HB; Wang L; Yun QZ; Hu SN; Wang DM
Pharmacogenomics J; 2009 Dec; 9(6):380-94. PubMed ID: 19636337
[TBL] [Abstract][Full Text] [Related]
9. Changes at the CYP2C locus and disruption of CYP2C8/9 linkage disequilibrium in patients with essential tremor.
Martínez C; García-Martín E; Alonso-Navarro H; Jiménez-Jiménez FJ; Benito-León J; García-Ferrer I; Vázquez-Torres P; Puertas I; Zurdo JM; López-Alburquerque T; Agúndez JA
Neuromolecular Med; 2007; 9(2):195-204. PubMed ID: 17627038
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
[TBL] [Abstract][Full Text] [Related]
11. Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies.
Nowak MP; Sellers EM; Tyndale RF
Clin Pharmacol Ther; 1998 Oct; 64(4):378-83. PubMed ID: 9797794
[TBL] [Abstract][Full Text] [Related]
12. Linkage disequilibrium between the CYP2C19*17 and CYP2C8*2 alleles in populations of African descent.
Suarez-Kurtz G
Eur J Clin Pharmacol; 2011 Feb; 67(2):211-2. PubMed ID: 20890775
[No Abstract] [Full Text] [Related]
13. Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution.
Janha RE; Worwui A; Linton KJ; Shaheen SO; Sisay-Joof F; Walton RT
BMC Evol Biol; 2014 Apr; 14():71. PubMed ID: 24690327
[TBL] [Abstract][Full Text] [Related]
14. Direct evidence for the higher frequency of CYP2C19 allelic heterozygotes in Chinese subjects than in white subjects.
Xie HG
Clin Pharmacol Ther; 1997 Dec; 62(6):691-2. PubMed ID: 9433397
[No Abstract] [Full Text] [Related]
15. Two single-tube tetra-primer assays to detect the CYP2C19*2 and *3 alleles of S-mephenytoin hydroxylase.
Hersberger M; Marti-Jaun J; Rentsch K; Hänseler E
Clin Chem; 2001 Apr; 47(4):772-4. PubMed ID: 11274039
[No Abstract] [Full Text] [Related]
16. Distribution of polymorphisms in the CYP2C9 gene and CYP2C19/CYP2C9 haplotypes among Venezuelan populations.
Flores-Gutiérrez S; Rodríguez-Larralde Á; Vívenes de Lugo M; Castro de Guerra D
Ann Hum Biol; 2017 Mar; 44(2):191-198. PubMed ID: 27230833
[TBL] [Abstract][Full Text] [Related]
17. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.
Aynacioglu AS; Sachse C; Bozkurt A; Kortunay S; Nacak M; Schröder T; Kayaalp SO; Roots I; Brockmöller J
Clin Pharmacol Ther; 1999 Aug; 66(2):185-92. PubMed ID: 10460072
[TBL] [Abstract][Full Text] [Related]
18. Distribution of CYP2C19*17 allele and genotypes in an Indian population.
Anichavezhi D; Chakradhara Rao US; Shewade DG; Krishnamoorthy R; Adithan C
J Clin Pharm Ther; 2012 Jun; 37(3):313-8. PubMed ID: 21916910
[TBL] [Abstract][Full Text] [Related]
19. [Genetic polymorphism of the CYP2C subfamily].
Chiba K
Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):15-21. PubMed ID: 9755458
[TBL] [Abstract][Full Text] [Related]
20. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.
Ibeanu GC; Goldstein JA; Meyer U; Benhamou S; Bouchardy C; Dayer P; Ghanayem BI; Blaisdell J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1490-5. PubMed ID: 9732415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
